PFAS and the Heart: Understanding Cardiovascular Risk
The C8 Health Project’s 2004 finding of a “probable link” between PFOA exposure and high cholesterol in the West Virginia exposure community was among the first human evidence for PFAS cardiovascular effects. Two decades of subsequent research has built a substantial and coherent evidence base linking PFAS exposure to elevated total cholesterol, LDL cholesterol, triglycerides, altered lipid metabolism, hypertension, and—with increasing epidemiological consistency—clinical cardiovascular disease outcomes including coronary artery disease and cardiovascular mortality. Understanding the mechanisms and magnitude of these effects is important for clinical management of PFAS-exposed individuals and for regulatory risk assessment that now explicitly incorporates cardiovascular endpoints.
PFAS and Cholesterol: The Strongest Association
The association between PFAS and elevated cholesterol is among the most consistently replicated findings in PFAS epidemiology across dozens of independent studies covering multiple countries, exposure levels, and PFAS compounds. NHANES analyses find that adults in the highest PFAS quartile have total cholesterol approximately 10–20 mg/dL higher than those in the lowest quartile—a clinically meaningful difference that corresponds to a 5–10% increase in cardiovascular risk. The association is consistent for PFOS, PFOA, PFNA, and PFHxS; dose-dependent across exposure ranges; and biologically plausible through PFAS competition with fatty acids for binding to the fatty acid-binding protein that regulates hepatic lipid metabolism and cholesterol homeostasis. The 2022 ATSDR Clinical Guidance for Healthcare Professionals specifically recommends lipid monitoring for individuals with elevated PFAS blood concentrations.
Hypertension and Cardiovascular Events
Beyond lipid effects, PFAS have been associated with elevated blood pressure in several birth cohort studies—particularly examining pregnancy-induced hypertension (preeclampsia). The C8 Health Project found a probable link between PFOA and pregnancy-induced hypertension. A 2021 meta-analysis of 11 prospective studies covering 26,000 adults found that higher PFAS exposure was associated with 15–25% higher odds of hypertension. The most recent evidence on clinical cardiovascular outcomes: a 2023 Lancet Planetary Health study following 1,100 Faroese adults from birth to age 34 found that higher prenatal PFAS exposure was significantly associated with elevated blood pressure and early subclinical atherosclerosis in young adulthood—providing prospective evidence that prenatal PFAS exposure produces cardiovascular effects measurable decades later.
Mechanisms: How PFAS Affect Lipid and Cardiovascular Function
Multiple mechanisms have been proposed and investigated for PFAS cardiovascular effects: Hepatic lipid metabolism disruption: PFAS activate PPAR-alpha (a nuclear receptor that regulates fatty acid oxidation and lipid metabolism in the liver), producing increased hepatic cholesterol and triglyceride synthesis. Bile acid disruption: PFAS alter bile acid pool composition, affecting cholesterol metabolism and fecal cholesterol excretion. Thyroid hormone disruption: PFAS-associated alterations in thyroid hormone status affect cardiac function and lipid metabolism. Oxidative stress: PFAS generate reactive oxygen species in liver and vascular endothelium, potentially promoting atherosclerosis. Epigenetic effects: PFAS have been shown to alter DNA methylation patterns at loci associated with cardiovascular risk in epidemiological studies.
PFAS cardiovascular effects—particularly cholesterol elevation—represent a population-level health burden that, even at modest individual effect sizes, translates into substantial cardiovascular disease incidence across the millions of people with PFAS exposure above current MCLs.